University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
Treatment to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Description

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Invasive fungal infections are infections caused by organisms called fungi that enter the blood stream and can then spread to different organs in the body. Chemotherapy used to treat AML severely reduces the body’s natural infection fighting ability. Preventing invasive fungal infections due to chemotherapy is therefore very important for the study treatment success of people with AML.

This study is organized by Children’s Oncology Group (COG). The overall goal of this study is to compare the effects of 2 antifungal drugs: caspofungin and fluxonazole on people getting treatment for AML. On this study, you will either get caspofungin or fluconazole. You will not get both drugs.

Approximately 6 people will take part in this study conducted by investigators at the University of Iowa.  Approximately 550 people will be enrolled worldwide.

Start Date
April 4, 2011
End Date
April 4, 2016
Gender Preference
None
Age Group
0 - 30 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Julie de la Garza, RN (319) 36-3749

Department
Keywords
ACCL0933 ; Acute Myeloid Leukemia (AML) ; cancer ; Caspofungin ; Children ; Fluconazole ; pediatric ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.